At Fluxion, we’re passionate about delivering cell-based and cell-free solutions that facilitate the transformation of research discoveries into new ways to diagnose and treat patients. By characterizing molecular and cellular mechanisms of disease, Fluxion’s platforms help bridge the translational medicine gap, enabling rapid advances in disease research, drug discovery, and the development of diagnostic tests.
Study published in Translational Oncology highlights growing interest in non-invasive oncology diagnostics
Fluxion Biosciences announced the publication of a paper entitled “Mutational Analysis of Circulating Tumor Cells Using a Novel Microfluidic Collection Device and qPCR Assay”, demonstrating the capability to detect mutations in circulating tumor cells (CTCs) from cancer patients. CTCs are cells that disseminate from primary tumors and contribute to the spread of the disease to other parts of the body. The IsoFlux System recovers these rare tumor cells from a standard blood draw and prepares them for molecular analysis.
A key finding of the study, published in Translational Oncology, shows that the IsoFlux System recovers enough CTCs for mutational profiling in a majority of patients tested (87% for colorectal and 95% for prostate cancer). For colorectal patients, 50% displayed a CTC-based KRAS mutation, a level that is in line with tissue-based mutational profiling of this indication. The high sensitivity of the IsoFlux system was also demonstrated by comparing CTC recovery from matched prostate patient samples as compared to other leading instruments. The percent of patients with five or more CTCs per 7mL blood draw was 95% with IsoFlux, compared to 36% with CellSearch.
“The ability to track clinically relevant biomarkers longitudinally is one of the primary advantages of CTCs,” said Michael Schwartz, Program Director at Fluxion Biosciences. “By combining the IsoFlux System and a sensitive qPCR-based mutation assay, this workflow provides a complete solution to monitoring oncogene mutational changes over time with high success rates.”
Customers have adopted the IsoFlux System to isolate and characterize CTCs for biomarkers including gene expression, mutations (qPCR and next generation sequencing), and chromosomal aberrations. More information can be found at www.fluxionbio.com/IsoFlux.
About Fluxion Biosciences Fluxion Biosciences provides cellular analysis tools for use in critical life science, drug discovery, and diagnostic applications. Products include the BioFlux™ System for studying cellular interactions, the IonFlux™ System for high throughput patch clamp measurements, and the IsoFlux™ System for circulating tumor cells. Fluxion’s systems are designed to replace laborious and difficult assays by providing intuitive, easy-to-use instruments for cell-based analysis. For more information about Fluxion Biosciences, visit www.fluxionbio.com.